Hoylecohen LLC Boosts Holdings in Amgen Inc. (NASDAQ:AMGN)

Hoylecohen LLC lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 34.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,709 shares of the medical research company’s stock after buying an additional 1,218 shares during the quarter. Hoylecohen LLC’s holdings in Amgen were worth $1,356,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of AMGN. BOK Financial Private Wealth Inc. purchased a new stake in Amgen in the 4th quarter worth approximately $29,000. Planned Solutions Inc. purchased a new position in shares of Amgen during the 4th quarter valued at $30,000. Delos Wealth Advisors LLC boosted its holdings in Amgen by 2,500.0% in the 4th quarter. Delos Wealth Advisors LLC now owns 104 shares of the medical research company’s stock worth $30,000 after buying an additional 100 shares during the period. Providence Capital Advisors LLC purchased a new stake in Amgen in the 3rd quarter worth $30,000. Finally, Hartford Financial Management Inc. raised its holdings in Amgen by 56.9% during the fourth quarter. Hartford Financial Management Inc. now owns 113 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 41 shares during the period. 76.50% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on AMGN. Raymond James assumed coverage on Amgen in a report on Thursday, March 28th. They issued a “market perform” rating on the stock. Mizuho boosted their target price on shares of Amgen from $223.00 to $235.00 and gave the stock a “neutral” rating in a report on Thursday, May 9th. Morgan Stanley raised their target price on shares of Amgen from $271.00 to $310.00 and gave the company an “equal weight” rating in a research note on Friday, May 3rd. StockNews.com upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. Finally, Truist Financial restated a “buy” rating and set a $320.00 price objective on shares of Amgen in a research report on Friday, April 12th. Ten research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat.com, Amgen presently has an average rating of “Moderate Buy” and an average target price of $305.65.

Amgen Stock Down 0.2 %

Shares of Amgen stock traded down $0.66 during trading on Friday, hitting $305.84. 2,425,864 shares of the stock traded hands, compared to its average volume of 2,869,476. The company has a current ratio of 1.42, a quick ratio of 0.98 and a debt-to-equity ratio of 11.96. Amgen Inc. has a 52-week low of $211.71 and a 52-week high of $329.72. The stock’s fifty day simple moving average is $285.02 and its 200 day simple moving average is $285.51. The firm has a market cap of $164.06 billion, a P/E ratio of 43.69, a price-to-earnings-growth ratio of 2.77 and a beta of 0.60.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, May 2nd. The medical research company reported $3.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.76 by $0.20. The firm had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.45 billion. Amgen had a net margin of 12.74% and a return on equity of 156.21%. The company’s quarterly revenue was up 22.0% on a year-over-year basis. During the same period last year, the firm earned $3.98 earnings per share. On average, equities analysts predict that Amgen Inc. will post 19.47 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 17th will be given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 2.94%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is 128.57%.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 2,117 shares of the business’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $313.09, for a total transaction of $662,811.53. Following the transaction, the senior vice president now directly owns 9,883 shares in the company, valued at approximately $3,094,268.47. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 0.69% of the company’s stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.